CD274 and neoplasm: There are now four anti–PD-1 Abs (nivolumab, pembrolizumab, cemiplimab, and dostarlimab) and three anti–PD-L1 Abs (avelumab, atezolizumab, and durvalumab) approved in the United States for indications that stretch across at least 15 different tumor types (1, 2).